Cargando…
Odevixibat: First Approval
Odevixibat (Bylvay™) is a small molecule inhibitor of the ileal bile acid transporter being developed by Albireo Pharma, Inc. for the treatment of various cholestatic diseases, including progressive familial intrahepatic cholestasis (PFIC). In July 2021, odevixibat received its first approval in the...
Autor principal: | Deeks, Emma D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550539/ https://www.ncbi.nlm.nih.gov/pubmed/34499340 http://dx.doi.org/10.1007/s40265-021-01594-y |
Ejemplares similares
-
Abrocitinib: First Approval
por: Deeks, Emma D., et al.
Publicado: (2021) -
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Sarecycline: First Global Approval
por: Deeks, Emma D.
Publicado: (2019) -
Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019) -
Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021)